There is also evidence accumulating to support RET activation and signaling in the pathogenesis of a subset of estrogen receptor α positive breast cancer [30] and overexpression of RET has been reported in prostate, pancreatic, neural crest derived tumors, bile duct carcinomas, melanoma, and lung cancers [31-37]. This evidence concerns the gene ESR1 and lung carcinoma.